MUMBAI: Cadila Healthcare is set to acquire Californiabased speciality pharma company Sentynl Therapeutics for $171 million as the company looks for alternative ways to build its US business that has been held back by regulatory inspections, officials in the know said.Sentynl acquires, develops and commercialises prescription products, according to the company's website. For FY16, sources said, Sentinyl's EBIDTA was $35 million and Cadila valued the firm for just a little less than five times EV EBIDTA multiple.The brand Abstral too has changed many hands. In 2011 it was acquired by Galena Pharma from the Swedish company called Orexo. Galena later sold it to Sentynl in 2015 for $12 million. In late 2011, they acquired Biochem, a domestic formulations business.Last December, Cadila's subsidiary Zydus Healthcare bought six brands from MSD Pharmaceuticals India, the local arm of US-based Merck Though the US has been a significant market for the company , it has been conservative about big buyouts.

Source: Economic Times January 18, 2017 02:50 UTC